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The facilitation of intraeranial surgery by the use of urea, to reduce brain bulk, has suggested that other osmotic agents nfight be useful for the same purpose. Wise and Chater ~ suggested that mannitol, a hexitol, long used by renologists in order to induce a diuresis, might be useful in this regard. It is readily available and its innoeuousness to man has been amply proven. It has a molecular weight triple that of m'ea, but this osmotic disadvantage of mannitol to urea might well be offset by the faet that mannitol is confined to the extraeellular space, for all practical purposes. This exclusion from the intracellular compartluent theoretically might be of further advantage in preventing a rebound of intraeranial pressure said to he noted on occasions after the use of urea. On the other hand, mannitol is excreted rapidly by the kidney (1 per cent per rain. of a loading dose) and its osmotic level in the blood is less prolonged than after urea, used in equivalent dosages and speed of injections. An advantage for mannitol is that renal disease does not appear to be a eontraindieation for its use; indeed, it has been advocated recently for use in patients with renal disease, in order to prevent urinary shutdown. *
DOSAGE
In calculating the amount of mannitol to use for optimum clinical advantage, we have been guided by our previous experiences with urea. It has been our impression that urea * Presented at meeting of the Ilarvey Cushing Society, Chicago, Illinois, May 1, 196~2.
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Mannitol furnished courtesy of Travenol 1,aboratories, Inc., Morton (;rove, Illinois. used in the recommended (loses of 1 to 1 89 gin. per kg. as a routine before craniotomy has been mmeeessary. Smaller doses of approximately 89 gm. per kg. given intravenously in 15 min., had been sufficient to relax the brain for most procedures, lhus facilitating the turning of the bone flap and preventing herniation of the brain upon opening the dura mater an(t, when necessary, permitting easy access to the r the elnptying of which completely relaxes the brain for ample exposure of structures beneath the brain. This smaller (lose of urea had not caused the venous ooze seen with the use of the recommended larger closes of urea, presumably resuiting from the more drastic shrinkage of brain bulk and a concomitant greater increase in intravascular volume. 4 Furthermore, these smaller doses have not masked the very occasional state of shock, that we feel has occurred at times, with routine use of' 1 to 1 89 gin. per kg. doses of urea, particularly in the older patient. Consequently, we ha~ e used, on the average, a dose of 1 gin. of mannitol per kg. of body weight given in s to ~5 per cent solutions intravenously in a period varying from 10 to lfi rain. This has achieved a maximum rise in osmolarity of serum amounting to ~0 to 80 millioslnols at the terlnination of the infusion, with a decline in osmotieity to control levels over a period of approximately 8 hem's.
We are in the process of determining the effects of variations in the speed of infusion of urea and mannitol upon esmolarity of serum and resulting influences on eerebrospinal-fluid pressure. It is reasonable to assume that the osmotic gradient achieved between blood and brain is the factor that, produces a reduction in brain bulk with the use of i n t r a v e n o u s m a n n i t o l or urea. I t further is to be assumed t h a t the speed of infusion of these agents, as well as the t o t a l dosage used, are i m p o r t a n t in achieving this osmotic gradient. These provide two variables t h a t are capable of control in achieving an o p t i m u m clinical effect.
I n 5 experiments (Table 1) initial spinal-fluid pressure, as n o t e d previously b y others, 2.3 seems to be an i m p o r t a n t factor in d e t e r m i n i n g the a m o u n t of decrease in pressure achieved, our d a t a (Table 1) indicate a relationship to the m a g n i t u d e of the osmotic change created. Of course, our d a t a are still quite limited and this point does bear further elucidation.
RESULTS
Mannitol was used as an operative preparation for 34 patients. Of these, 21 had supratentorial tumors, 4 of which were meningiomas. There were 2 with posterior-fossa tumors and 4 patients had a retrogasserian rhizotomy. 
DISCUSSION
The purpose of this presentation is twofold. First, to confirm the recommendation for the use of mannitol as another osmotic agent for control of brain bulk during intracranial surgery as being safe and effective. Second, to suggest that the method of administration of these osmotic agents (urea and mannitol) as to dosage and speed of infusion needs further investigation. Empirically, in our hands, smaller than recommended closes appear to be effective and create less difficulties. So far, our studies in the laboratory on mannitol given in doses of 1 gin. per kg. (Table 1 ) appear to correlate with previously reported studies of Javid and Settlage, 2 Langfitt, 3 and Wise and Chater 6 to indicate that there is a relationship between dosage used and increase in osmolarity of serum achieved, when measured, and percentage decrease of cerebrospinal-fluid pressure produced and the length of time this de- (Table ~) . The salient question in the use of these agents appears, to us, to be the determination of the proper osmotic change that should be produced to yield the optimum reduction of brain bulk during surgery or in treatment of cerebral edema. It does not seem difficult to determine what dosage of an osmotic agent should be used for maximum reduction of brain bulk, but the criteria for the optimum dosage to use leave room for further investigation.
SUMMARY
In summary, our experience corroborates the findings of others as to safety and efficacy of mannitol as an osmotic agent for reduction of brain bulk during intraeranial surgery, Infusion of mannitol was given 34 patients preoperatively. In all, adequate exposure and relaxation of the brain occurred. This was achieved despite the fact that smaller than recommended doses were utilized.
Our data from controlled studies indicate that the magnitude of decrease in cerebrospinal-fluid pressure was related to the osmotic gradient achieved at the termination of infusion. In turn, this osmotic gradient can be varied not only by the total dosage used, but also by the speed of injection. The combination of these several factors in order to achieve an optimum result is being investigated currently in our laboratory. DISCUSSION DR. BUt~TON L~ WISE:* We are gratified that Dr. Shenkin and his associates have confirmed our findings that hypertonic mannitol solutions are effective in lowering cerebrospinal-fluid pressure and decreasing brain mass. We began to look for another osmotic agent because of certain theoretical and practical objections to the use of urea. The distribution of urea throughout total body water may cause "rebound overshoot" of cerebrospinal-fluid pressure. Reports of toxicity of urea include changes in the electrocorticogratn and electrocardiogram; occasional hemoglobinuria; venous thrombosis; and necrosis of tissue and sloughs in case of extravenous extravasation of urea. Another disadvantage of urea has been its instability, which necessitates making the solution from the lyophilized preparation, and the fact that, if not used, it may have to be discarded.
On theoretical grounds, it appeared to us that hypertonic mannitol solution would be a safe and effective agent to lower cerebrospinal-fluid pressure and decrease brain mass. Extensive use of mannitol in the past had established its lack of toxicity and inertness. Preparation of the hypertonie solution is by simple heat sterilization and the solution is relatively inexpensive and stable. In previous reports, we have emphasized the fact that because of its extracellular distribution and rapid excretion it seemed that mannitol would be less likely to cause secondary "rebound overshoot" than a substance like urea, which eventually is distributed throughout total body water, even if its entry into the brain and eerebrospinal fluid is relatively slow.
We have administered hypertonic mannitol solution to 67 patients. These have included ~2 with gliomata, 11 with intracranial aneurysms, 8 with meningiomas, 7 with pituitary tumors and craniopharyngiomas, 5 with * Read by Dr. John E. Adams. metastatic carcinoma to the brain, 4 undergoing hypophysectomy, ~ with "pseudo-tumor cerebri," 1 with a frontal arteriovenous malformation and intracerebral hemorrhage, 1 with brain abscess, 1 undergoing section of the trigeminal nerve in the posterior fossa, and 5 miscellaneous cases. In ahnost all instances, decrease in intracranial pressure and brain mass has been satisfactory as judged by the various neurosurgeons at our Center who have used it.
Some of the situations in which hypertonic mannitol has proved useful are: (1) when the dura mater is to be opened and intracranial tension is high, (~) to facilitate retraction of the brain in the approach to deep structures, (3) to facilitate dural closure when intracranial tension remains elevated, (4) temporary reversal of evidence of decompensating increased intracranial pressure and brain herniation, and (5) the treatment of "brain swelling" coming on several days after craniotomy.
We currently use a ~0 per cent solution of mannitol in distilled water. We generally have used a higher dosage than Dr. Shenkin, namely ~.5 to 3 gin. per kg. and occasionally have given as much as ~.~5 gin. per kg. If the infusion is started after the bone flap is turned, decrease in intracranial tension usually is apparent in 15 to 30 rain. We have administered the solution as rapidly as 1 1. in 30 min., although generally 69 to 90 rain. are taken for the complete infusion. There may be transient elevations of blood pressure of 10 to ~0 ram. Hg and other evidence has been reported that hypertonic mannitol solution, as well as urea, causes a transient increase in volume of plasma. However, we have not seen evidence of cardiocirculatory overload. Venous thrombosis has not been a problem and in 1 instance in which mannitol solution inadvertently infiltrated in the subcutaneous tissue, there was no subsequent necrosis of tissue or slough. As Dr. Shenkin pointed out, we are not aware of any contraindicafion to the use of mannitol in the presence of renal, hepatic, or cardiac disease except for the possibility of sudden expansion of circulatory volume. We have used mannitol concurrent with hypothermia and found no incompatibility. We have also used mannitol with and following hyperventilation. In S instances mamfitol resulted in a decrease in brain mass after there was no apparent effect on brain mass from ~0 to 30 min. of continuous hyperventilation under anesthesia. In 1 instance, the decrease iu hrain mass that followed ventricular drainage was augmented by subsequent administration of mannitol. Our initial studies on osmolaritics are fairly similar t() those reported by Dr. Shenkin.
As might t)e expected from the similarity of aqueous humor and cerebrospinal fluid, hypertonic mannitol solution has been shown to lower ocular pressure and in preliminary studies has heen found to be effective in lowering ocular pressure in patients with glaucoma.
DR. HENRY A. SHENKIN: I think that the doses used at the University of California are not really very different from what we are using, if you consider that we infuse mannitol more rapidly than they do. I think it will turn out that the osnmtic gradient created is the critical factor. This is the point, I think, that has to be investigated in the use of these osmotic agents for cerebral decompression.
